LyP-1 TFA
目录号 : GC61471
LyP-1TFA是一种环状9个氨基酸的肿瘤的定位肽，在多种肿瘤相关细胞中，选择性结合其p32receptor蛋白。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
LyP-1 TFA is a cyclic 9‐amino‐acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells[1].
LyP-1 TFA (8 weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1].The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106 photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1].
[1]. Fan Zhang, et al.Imaging tumor-induced sentinel lymph node lymphangiogenesis with LyP-1 peptide. Amino Acids. 2012 Jun;42(6):2343-51. [2]. Ningning Song, et al. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv. 2019 Dec;26(1):363-375.
| Cas No. | SDF | ||
| 分子式 | C38H66F3N17O14S2 | 分子量 | 1106.16 |
| 溶解度 | 储存条件 | -20°C, away from moisture | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.904 mL | 4.5201 mL | 9.0403 mL |
| 5 mM | 0.1808 mL | 0.904 mL | 1.8081 mL |
| 10 mM | 0.0904 mL | 0.452 mL | 0.904 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet